Vaxine Pty Ltd
CAGE Code: Z0ED5
NCAGE Code: Z0ED5
Status: Active
Type: Commercial Supplier
Summary
Vaxine Pty Ltd is an Active Commercial Supplier with the Cage Code Z0ED5.
Address
Flinders Medical Centre
1 Flinders Dr
Po Box 18
Bedford Park
Sa
5042
Australia
Points of Contact
No Points of Contact...
Related Information
No Related Information...
People who viewed this 'CAGE Code' also viewed...
North Power Construction Company Newyork Eagle Construction Company Super Jet Group Sina Aria Logistic And Trading Arif Noor Construction Company,Ltd Melad Abrar Intl. Transit And Bashir Qayum Logistics Services Dostamani Construction Company Sayed Zawar Ali Khan Renewable Energy Agency Jlcc Mohammad Eisa Sardarzada Well Naweed Insaaf Construction Company Aria Roshan Trading Company Inc Abdul Waris Kamran Road And Priority Development Stratigic Co Ace Limited Liability Company Asct Group Seroosh Services Lux Star Construction Company
Frequently Asked Questions (FAQ) for CAGE Z0ED5
- What is CAGE Code Z0ED5?
- Z0ED5 is the unique identifier used by NATO Organizations to reference the physical entity known as Vaxine Pty Ltd located at Flinders Medical Centre, 1 Flinders Dr, Po Box 18, Bedford Park, Sa, 5042, Australia.
- Who is CAGE Code Z0ED5?
- Z0ED5 refers to Vaxine Pty Ltd located at Flinders Medical Centre, 1 Flinders Dr, Po Box 18, Bedford Park, Sa, 5042, Australia.
- Where is CAGE Code Z0ED5 Located?
- CAGE Code Z0ED5 is located in Bedford Park, Australia.
Contracting History for CAGE Z0ED5 Most Recent 25 Records
- 75N93018C00044
- Djuvant Development Program
- 31 Jul 2020
- Djuvant Development Program
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $3,967,532.00
- Department Of Health And Human Services (Hhs)
- 75N93018C00024
- To Advance The Novel H7-Advax Pandemic Vaccine Candidates Through To Phase 1 Clinical Trials Through Delivery To The Government Of: Preliminary Data Regarding Adjuvant For Formulations (Base Requirement/Clin 001); Manufactured Product (Release) For S
- 13 Mar 2020
- To Advance The Novel H7-Advax Pandemic Vaccine Candidates Through To Phase 1 Clinical Trials Through Delivery To The Government Of: Preliminary Data Regarding Adjuvant For Formulations (Base Requirement/Clin 001); Manufactured Product (Release) For S
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $2,835,478.00
- Department Of Health And Human Services (Hhs)
- 75N93018C00044
- Eo14042 Adjuvant Development Program
- 14 Oct 2021
- Eo14042 Adjuvant Development Program
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $5,138,039.00
- Department Of Health And Human Services (Hhs)
- HHSN272201400053C
- Igf::Ot::Igf Adjuvant Discovery Program
- 20 Sep 2018
- Igf::Ot::Igf Adjuvant Discovery Program
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $10,373,491.00
- Department Of Health And Human Services (Hhs)
- HHSN272201400053C
- Adjuvant Discovery Program
- 24 Nov 2021
- Adjuvant Discovery Program
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $11,281,569.40
- Department Of Health And Human Services (Hhs)
- 75N93018C00024
- Igfotigf - "Advanced Development Of Vaccine Candidates For Biodefense And Emerging Infectious Diseases".
- 28 Aug 2019
- Igfotigf - "Advanced Development Of Vaccine Candidates For Biodefense And Emerging Infectious Diseases".
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $2,835,478.00
- Department Of Health And Human Services (Hhs)
- 75N93018C00024
- To Advance The Novel H7-Advax Pandemic Vaccine Candidates Through To Phase 1 Clinical Trials Through Delivery To The Government Of: Preliminary Data Regarding Adjuvant For Formulations (Base Requirement/Clin 001); Manufactured Product (Release) For S
- 12 Aug 2020
- To Advance The Novel H7-Advax Pandemic Vaccine Candidates Through To Phase 1 Clinical Trials Through Delivery To The Government Of: Preliminary Data Regarding Adjuvant For Formulations (Base Requirement/Clin 001); Manufactured Product (Release) For S
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $6,368,354.00
- Department Of Health And Human Services (Hhs)
- HHSN272201400053C
- Igf::Ot::Igf Adjuvant Discovery Program
- 2 Aug 2018
- Igf::Ot::Igf Adjuvant Discovery Program
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $10,373,491.00
- Department Of Health And Human Services (Hhs)
- 75N93018C00044
- Adjuvant Development Program
- 12 Jul 2021
- Adjuvant Development Program
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $5,138,039.00
- Department Of Health And Human Services (Hhs)
- 75N93018C00044
- Exercising Option 3, Year 4.
- 14 Jun 2022
- Exercising Option 3, Year 4.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $6,690,025.00
- Department Of Health And Human Services (Hhs)
- HHSN272201400053C
- Adjuvant Discovery Program
- 11 Sep 2019
- Adjuvant Discovery Program
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $10,786,491.00
- Department Of Health And Human Services (Hhs)
- 75N93018C00044
- Igf::Ot::Igf Adjuvant Development Program
- 10 Sep 2018
- Igf::Ot::Igf Adjuvant Development Program
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $2,494,333.00
- Department Of Health And Human Services (Hhs)
- 75N93018C00044
- Adjuvant Development Program
- 1 Aug 2022
- Adjuvant Development Program
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $6,690,025.00
- Department Of Health And Human Services (Hhs)
- HHSN272201400053C
- Adjuvant Discovery Program
- 7 Apr 2020
- Adjuvant Discovery Program
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $11,286,491.00
- Department Of Health And Human Services (Hhs)
- 75N93018C00024
- To Advance The Novel H7-Advax Pandemic Vaccine Candidates Through To Phase 1 Clinical Trials Through Delivery To The Government Of: Preliminary Data Regarding Adjuvant For Formulations (Base Requirement/Clin 001); Manufactured Product (Release) For S
- 10 Aug 2021
- To Advance The Novel H7-Advax Pandemic Vaccine Candidates Through To Phase 1 Clinical Trials Through Delivery To The Government Of: Preliminary Data Regarding Adjuvant For Formulations (Base Requirement/Clin 001); Manufactured Product (Release) For S
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $6,368,354.00
- Department Of Health And Human Services (Hhs)
- 75N93018C00044
- Adjuvant Development Program
- 21 Apr 2021
- Adjuvant Development Program
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $3,967,532.00
- Department Of Health And Human Services (Hhs)
- 75N93018C00044
- Adjuvant Development Program
- 17 Aug 2021
- Adjuvant Development Program
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $5,138,039.00
- Department Of Health And Human Services (Hhs)
- HHSN272201400053C
- Igf::Ot::Igf Adjuvant Discovery Program
- 24 Jun 2019
- Igf::Ot::Igf Adjuvant Discovery Program
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $10,373,491.00
- Department Of Health And Human Services (Hhs)
- 75N93018C00044
- Adjuvant Development Program
- 2 Jun 2023
- Adjuvant Development Program
- National Institutes Of Health Nci
- Department Of Health And Human Services (Hhs)
- $6,690,025.00
- Department Of Health And Human Services (Hhs)
- 75N93018C00024
- Igf::Ot::Igf - "Advanced Development Of Vaccine Candidates For Biodefense And Emerging Infectious Diseases".
- 20 Sep 2018
- Igf::Ot::Igf - "Advanced Development Of Vaccine Candidates For Biodefense And Emerging Infectious Diseases".
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $2,835,478.00
- Department Of Health And Human Services (Hhs)